Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
UNLABELLED: Our objective was to evaluate the pharmacokinetics, normal tissue distribution, radiation dosimetry, and toxicology of human epidermal growth factor (hEGF) labeled with (111)In ((111)In-diethylenetriaminepentaacetic acid [DTPA]-hEGF) in mice and rabbits. METHODS: (111)In-DTPA-hEGF (3.6...
Príomhchruthaitheoirí: | Reilly, R, Chen, P, Wang, J, Scollard, D, Cameron, R, Vallis, K |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2006
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
de réir: Bailey, K, et al.
Foilsithe / Cruthaithe: (2007) -
111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
de réir: Cornelissen, B, et al.
Foilsithe / Cruthaithe: (2012) -
111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
de réir: Cornelissen, B, et al.
Foilsithe / Cruthaithe: (2012) -
111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
de réir: Cornelissen, B, et al.
Foilsithe / Cruthaithe: (2012) -
A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
de réir: Reilly, R, et al.
Foilsithe / Cruthaithe: (2004)